UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	9		
	FORM	И 6-К	
PURSUA	ANT TO SECT	GN PRIVATE ISSUER ION 13a-16 OR 15d-16 EXCHANGE ACT OF	1934
	For the montl	of July, 2019	
(Commission File N	(umber: 001-36815	
		harma A/S as Specified in Its Charter)	
	Tuborg Bo DK-2900 Deni (Address of princip	Hellerup nark	
Indicate by check mark whether the registrant files or will	l file annual reports	under cover of Form 20-F or I	Form 40-F.
	Form 20-F ⊠	Form 40-F □	
Indicate by check mark if the registrant is submitting the I	Form 6-K in paper	as permitted by Regulation S-T	`Rule 101(b)(1): □

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \Box

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-228576, 333-203040, 333-210810, 333-21512, 333-213412, 333-214843 and 333-216883) and Form F-3 (Registration Numbers 333-209336, 333-211511, 333-216882, 333-223134 and 333-225284) of Ascendis Pharma A/S (the "Company") (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

On July 18, 2019, the Company announced that it had filed an Investigational New Drug application with the U.S. Food and Drug Administration to enable the Company's Phase 2 trial of TransCon CNP, a long-acting prodrug of C-type natriuretic peptide.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 18, 2019

Ascendis Pharma A/S

By: /s/ Michael Wolff Jensen

Michael Wolff Jensen

Chairman and Senior Vice President, Chief Legal Officer